Time in range

There are 101 papers on time in range in aging research: 28 trials and 56 observational studies in people, 12 reviews.

Biomarker

101 papers study it83 more mention it58 findings

23 new papers in 30 daysSee all 184 papers on time in range

At a glance

Higher time in range is associated with less sarcopenia and mild cognitive impairment in older people with type 2 diabetes. Physical-function links differ across observational studies, including a study with no clear link in older patients with type 2 diabetes. Trials report increases with caloric restriction and, in poorly controlled type 1 diabetes, hybrid closed-loop systems.

58 findings in 46 papers from 2021 to 2026, 17 of them since April 2026

“Domain-wise analysis shows that as TIR increased, the scores obtained for the Role Limitation due to Physical Health domain also increased significantly (p-value = 0.002), indicating that higher TIR correlated with fewer Role Limitations due to Physical Health.”
Quality of Life and Its Association With Time in Range Among People With Type 2 Diabetes Mellitus Following Different Dietary Interventions: A Crossover Clinical TrialCureus2024doi:10.7759/cureus.57624
  • Human trial28
  • Humans56
  • In silico1

Interventions

20

Tirzepatide

upin humans7

7 studies
  1. Tirzepatide increases time in range in humans (from 53.2% (standard deviation [SD]: 18.2) to 78.9% (SD: 6.8) (p = 0.041)).

    Human trialup to 2 weeksn = 4

  2. Tirzepatide is linked with higher time in range in humans (+7.4% at 12 months).

    Humansadjunctive use in overweight or obese adults with T1D, compared with computer-matched controls12 monthsn = 61

  3. Tirzepatide is linked with higher time in range in humans (people with type 1 diabetes and obesity) (54.9% to 60.8%).

    Humanspeople with type 1 diabetes and obesity3 monthsn = 36

  4. Tirzepatide is linked with higher time in range in humans after switching from dulaglutide (42.7% to 50.8% (p = 0.02)).

    Humansafter switching from dulaglutiden = 14

  5. Tirzepatide is linked with higher time in range in humans (continuous glucose monitoring metrics).

    Humanscontinuous glucose monitoring metricsn = 62

  6. Tirzepatide is linked with higher time in range in humans (first tirzepatide administration, measured by continuous glucose monitoring) (53.2% to 78.9%).

    Humansfirst tirzepatide administration, measured by continuous glucose monitoringmean measurement period 10.5 daysn = 4

  7. Tirzepatide is linked with higher time in range in humans (adults with type 1 diabetes, uncontrolled comparison) (+12.6% (P = .002) for TIR; +10.7% (P = .0016) for TITR).

    Humansadults with type 1 diabetes, uncontrolled comparison8 monthsn = 26

  8. Tirzepatide is linked with higher time in range in a patient with type 1 diabetes and obesity (31% to 61% (doubled)).

    Humansin a patient with type 1 diabetes and obesity2.5 mg weekly titrated to 7.5 mg weekly12 weeksfemalesn = 1

More on Tirzepatide

Semaglutide

downin humans1upin humans1upin silico1

3 studies
  1. Semaglutide decreases time in range in humans following treatment discontinuation (median change −3.6% vs. 1.5%).

    Human trialfollowing treatment discontinuation3 monthsn = 38

  2. Semaglutide is linked with higher time in range in humans (as an add-on therapy to insulin in LADA patients).

    Humansas an add-on therapy to insulin in LADA patients6 monthsn = 68

  3. Semaglutide increases time in range in silico (added to AIDANET fully closed-loop system, versus placebo) (73% to 87% versus placebo).

    In silicoadded to AIDANET fully closed-loop system, versus placeboup to 1 mg/week

More on Semaglutide

Caloric restriction

upin humans2

2 studies
  1. Caloric restriction increases time in range in humans (92.4 ± 5% versus 81.4 ± 6.5%; p = 0.001).

    Human trialType 2 diabetes of ≤5 years; compared with calorie-matched time-restricted intermittent fastingContinuous calorie-restricted dietDaily energy intake reduced by 500 kcal/dayn = 51

  2. Caloric restriction improves time in range in humans (84.3% to 90.3%, P = 0.041).

    Human trial12‐weekn = 24

  3. Caloric restriction improves time in range in humans (84.3% to 90.3% (P = 0.041)).

    Human trial12 weeks

More on Caloric restriction

Chenopodium quinoa

upin humans1

1 study
  1. Chenopodium quinoa increases time in range in humans.

    Human trial14 weeksn = 60

  2. Chenopodium quinoa increases time in range in humans (early-stage T2DM) (94.52 ± 4.88% vs 87.83 ± 9.9%, P <0.05).

    Human trialearly-stage T2DMn = 60

More on Chenopodium quinoa

Acarbose

no changein humans1

1 study
  1. Acarbose showed no clear effect on time in range in humans (add-on to metformin, compared with sitagliptin add-on).

    Human trialadd-on to metformin, compared with sitagliptin add-on100 mg three times daily28 daysn = 701

  2. Acarbose showed no clear effect on time in range in humans (89.15% (78.12%, 95.07%) vs. 88.72% (77.44%, 94.73%)).

    Human trial28 daysn = 710

More on Acarbose

Combined aerobic and resistance training

upin humans1

1 study
  1. Combined aerobic and resistance training increases time in range in humans (type 2 diabetes mellitus; secondary comparison with aerobic training).

    Human trialtype 2 diabetes mellitus; secondary comparison with aerobic trainingn = 23

    Exercise mix linked to lower glucose in older type 2 diabetes patients

    Journal of science and medicine in sport

More on Combined aerobic and resistance training

Time-restricted feeding

upin humans1

1 study
  1. Time-restricted feeding improves time in range in adults with T2DM on stable GLP-1RA, during sleep.

    Human trialin adults with T2DM on stable GLP-1RA, during sleep8- to 10-hour eating window3 monthsn = 3

More on Time-restricted feeding

Open-source automated insulin delivery

upin humans1

1 study
  1. Open-source automated insulin delivery is linked with higher time in range in humans with adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors (63% to 73% at 12 months).

    Humanswith adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors12 monthsn = 357

More on Open-source automated insulin delivery

Insulin icodec + semaglutide

upin humans1

1 study
  1. Insulin icodec + semaglutide is linked with higher time in range in humans (54.8% to 78.1%; 95% CI 9.5–25.5).

    Humansdual therapy after switching from three or more glucose-lowering agents, compared with original therapyn = 66

More on Insulin icodec + semaglutide

Henagliflozin

upin humans1

1 study
  1. Henagliflozin increases time in range in severely hyperglycaemic T2DM patients (79.85% vs. 74.06%, p = 0.005).

    Human trialin severely hyperglycaemic T2DM patients7-dayn = 210

More on Henagliflozin

Morus alba

upin humans1

1 study
  1. Morus alba increases time in range in humans.

    Human trial14 daysn = 60

More on Morus alba

Intermittently scanned continuous glucose monitoring

upin humans1

1 study
  1. Intermittently scanned continuous glucose monitoring improves time in range in women with overweight or obesity participating in a structured lifestyle intervention (P = 0.03).

    Human trialin women with overweight or obesity participating in a structured lifestyle intervention12-weekfemalesn = 35

More on Intermittently scanned continuous glucose monitoring

Hybrid closed-loop system

upin humans1

1 study
  1. Hybrid closed-loop system increases time in range in humans (poorly controlled type 1 diabetes) (2-fold and 4-fold higher increase).

    Human trialpoorly controlled type 1 diabetes12 months

More on Hybrid closed-loop system

COVID-19 vaccine

downin humans1

1 study
  1. COVID-19 vaccine decreases time in range in humans (type 1 diabetes mellitus) (45.2% vs 52.6%).

    Human trialtype 1 diabetes mellitus7 daysn = 20

More on COVID-19 vaccine

All 20

Effects

2

Physical function

no changein humans1

1 study
  1. Time in range was not clearly linked with physical function in older patients with type 2 diabetes mellitus.

    Humansin older patients with type 2 diabetes mellitusn = 310

Sarcopenia

downin humans1

1 study
  1. Time in range is linked with less sarcopenia in elderly patients with type 2 diabetes mellitus.

    Humansin elderly patients with type 2 diabetes mellitusn = 280

More on Sarcopenia

Upstream

1

Sarcopenia without adiposity

downin humans1

1 study
  1. Sarcopenia without adiposity is linked with lower time in range in humans (sarcopenia without adiposity in frail older adults with diabetes).

    Humanssarcopenia without adiposity in frail older adults with diabetes

Associations

19

Physical activity

upin humans2

2 studies
  1. Physical activity is associated with time in range in humans (type 1 diabetes without confirmed cardiovascular autonomic neuropathy; adjusted analysis) (β = 15.22).

    Humanstype 1 diabetes without confirmed cardiovascular autonomic neuropathy; adjusted analysisself-reportedhigh versus low physical activityn = 75

  2. Physical activity is associated with time in range in humans (type 1 diabetes) (+8.0% TIR; -0.47% HbA1c).

    Humanstype 1 diabeteshighest activity quartilen = 423

More on Physical activity

Mild cognitive impairment

downin humans2OR 0.917–0.92

2 studies
  1. Time in range is associated with mild cognitive impairment in humans (OR 0.92).

    HumansPatients with type 2 diabetes mellitus and white matter hyperintensities; multivariable adjustmentn = 1,068

  2. Time in range is linked with a lower risk of mild cognitive impairment in humans (older adult patients with type 2 diabetes mellitus) (OR 0.917, 95% CI 0.867-0.969, P = 0.002).

    Humansolder adult patients with type 2 diabetes mellitusn = 203

More on Mild cognitive impairment

Quality of life

upin humans1

1 study
  1. Time in range is associated with quality of life in humans.

    Human trialsix monthsn = 56

  2. Time in range is associated with quality of life in humans (type 2 diabetes mellitus of less than 5 years' duration on Metformin only) (p = 0.002, p = 0.00).

    Human trialtype 2 diabetes mellitus of less than 5 years' duration on Metformin only14-dayn = 51

Cardiovascular autonomic neuropathy

downin humans1

1 study
  1. Cardiovascular autonomic neuropathy is associated with time in range in humans (type 1 diabetes; confirmed CAN versus no confirmed CAN) (56.0% vs. 72.0%).

    Humanstype 1 diabetes; confirmed CAN versus no confirmed CANn = 90

More on Cardiovascular autonomic neuropathy

Ramadan fasting

upin humans1

1 study
  1. Ramadan fasting is associated with time in range in humans (60.8% to 65.0%; P < .001).

    HumansType 2 diabetes receiving non-intensive diabetes therapy and using real-time continuous glucose monitoring; compared with pre-Ramadanduring Ramadann = 110

More on Ramadan fasting

IL-6

downin humans1

1 study
  1. Time in range is associated with IL-6 in humans (exploratory CGM substudy in pregnant women with obesity) (-0.23 [95%CI: -0.43,-0.02]; p=0.035).

    Humansexploratory CGM substudy in pregnant women with obesity24 weeks of gestationfemalesn = 18

More on IL-6

Cardiovascular disease or all-cause death

downin humans1HR 0.73

1 study
  1. Time in range is associated with cardiovascular disease or all-cause death in humans (Type 2 diabetes; adjusted model before mutual adjustment with HbA1c) (Adjusted HR 0.73 [0.61-0.87] per 20% TIR).

    HumansType 2 diabetes; adjusted model before mutual adjustment with HbA1cMedian 2.3 yearsn = 1,363

Total cholesterol

downin humans1

1 study
  1. Time in range is associated with total cholesterol in humans (type 2 diabetes mellitus; time in range >70%) (Total cholesterol decreased by 4.23 mg/dL in participants achieving TIR >70%).

    Humanstype 2 diabetes mellitus; time in range >70%12 weeks

More on Total cholesterol

Handgrip strength

mixedin humans1

1 study
  1. Time in range is associated with handgrip strength in older patients with type 2 diabetes mellitus.

    Humansin older patients with type 2 diabetes mellitusn = 310

Skeletal muscle mass index

upin humans1

1 study
  1. Time in range is associated with skeletal muscle mass index in older patients with type 2 diabetes mellitus.

    Humansin older patients with type 2 diabetes mellitusn = 310

More on Skeletal muscle mass index

All 19

Funding

1 grant since 2019

Health and Medical Research FundHK$1.4M

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 2Jan 2026: 10Feb 2026: 15Mar 2026: 16Apr 2026: 4May 2026: 2Jun 2026: 21Jul 2026: 0Aug 2026: 11Sep 2026: 1Oct 2026: 16Nov 2026: 10108 papers in 12 months

See all 184 papers on time in range